Tesofensine Dosing & Reconstitution Guide

Tesofensine functions as a triple monoamine reuptake inhibitor, targeting serotonin, norepinephrine, and dopamine pathways. By inhibiting the presynaptic reuptake of these neurotransmitters, Tesofensine elevates their synaptic concentrations, leading to appetite suppression through serotonergic pathways while enhancing thermogenesis and energy expenditure via noradrenergic and dopaminergic mechanisms. This central action distinguishes Tesofensine from GLP-1 agonists, which primarily operate through gut hormone signaling. The initial Phase 2 trials indicated an approximate 10% reduction in body weight over a 24-week period, positioning Tesofensine as one of the more effective weight loss agents in clinical research. Despite its non-peptide classification, its relevance in the weight loss discourse aligns it closely with peptide-based therapies, warranting further investigation into its full therapeutic potential.

The content presented on this page is intended solely for educational purposes and does not constitute medical advice. The dosing figures referenced are derived from published research findings and, where applicable, approved product labeling. It is crucial to note that these figures should not be interpreted as recommendations or protocols for administration. Volta Peptides is dedicated to supplying research materials intended exclusively for laboratory use, and these materials are not approved for human or veterinary applications. Furthermore, the information provided herein is not designed to diagnose, treat, cure, or prevent any medical condition. For any medical-related inquiries or decisions, consultation with a qualified healthcare professional is strongly advised.

In the context of research studies, Tesofensine has been administered orally, with a once-daily frequency reported in clinical trials. The dose range observed in the Phase 2 TIPO-1 obesity trial varied from 0.25 mg to 1.0 mg per day, with the 0.5 mg/day dose being carried into subsequent phases of development. These dosing parameters reflect the findings from the TIPO-1 trial, where the efficacy and safety profile of Tesofensine were evaluated. It is important to emphasize that these figures are derived from research contexts and should not be construed as recommendations for use outside of such settings.

Clinical studies indicate that Tesofensine can produce significant weight loss, with the Phase 2 RCT (TIPO-1, Astrup et al., Lancet 2008) reporting an average weight reduction of 10.6% over 24 weeks at a 0.5 mg daily dose, compared to a mere 2.2% in the placebo group among 203 obese participants. Additionally, trial data demonstrated that Tesofensine effectively suppresses appetite and reduces caloric intake, aligning with its mechanism of enhancing serotonergic pathways involved in satiety. Furthermore, Phase 2 findings suggest an increase in resting metabolic rate, attributed to noradrenergic stimulation, with effects appearing to be dose-dependent. While Tesofensine was initially developed for neurodegenerative disorders, its dopaminergic activity may also contribute to improvements in mood and motivation, although dedicated trials exploring these endpoints are still lacking.

The safety profile of Tesofensine, as reported in Phase 2 trials, includes notable increases in heart rate (averaging 5-8 bpm) and elevations in blood pressure at higher doses. Commonly reported side effects encompass dry mouth, insomnia, constipation, nausea, and diarrhea. Additionally, psychiatric effects such as anxiety and mood changes have been observed, which are consistent with the pharmacological action of monoamine reuptake inhibitors. Contraindications for the use of Tesofensine include uncontrolled hypertension or cardiovascular disease, concurrent administration of MAO inhibitors or other serotonergic drugs due to the risk of serotonin syndrome, and a history of psychiatric disorders, particularly severe anxiety or psychosis. These considerations underscore the importance of thorough safety evaluations in ongoing and future research.